Headlines
AbbVie to launch ovarian cancer drug in UK at US price
Published by Global Banking and Finance Review
Posted on September 29, 2025
1 min readLast updated: January 21, 2026
Global Banking and Finance Review
Company
Published by Global Banking and Finance Review
Posted on September 29, 2025
1 min readLast updated: January 21, 2026
AbbVie will launch its ovarian cancer drug Elahere in the UK at US prices, engaging with NICE for fair valuation. Elahere is an advanced antibody-drug conjugate.
(Reuters) -AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the UK at a list price equal to that in the U.S.
The company was one of the 17 drugmakers to receive letters from U.S. President Donald Trump in July outlining how they should cut prices to match those paid overseas.
The drugmaker said on Monday it was in discussions with Britain's cost-effectiveness watchdog National Institute for Health and Care Excellence to ensure the drug is valued fairly.
Elahere belongs to a new class of treatments called antibody-drug conjugates, also called "guided missile" drugs, that precisely target cancer cells, potentially reducing toxicity for other cells.
(Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo and Sriraj Kalluvila)
AbbVie plans to launch its ovarian cancer drug Elahere in the UK at a list price equal to that in the U.S.
AbbVie is in discussions with Britain's cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), to ensure the drug is valued fairly.
Elahere belongs to a new class of treatments called antibody-drug conjugates, which target cancer cells precisely, potentially reducing toxicity for other cells.
AbbVie was one of the 17 drugmakers that received letters from U.S. President Donald Trump in July, outlining how they should cut prices to match those paid overseas.
Explore more articles in the Headlines category
